Cardiac marker

Global Cardiac Marker Testing Market (2020 to 2025) - Emerging Markets to Offer High-Growth Opportunities for Players

Retrieved on: 
Monday, February 1, 2021

The global cardiac marker testing market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%.

Key Points: 
  • The global cardiac marker testing market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%.
  • Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market.
  • The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
  • Asia-Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period.

The Worldwide Cardiac Marker Testing Industry is Expected to Reach $5.5 Billion by 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 29, 2021

The global cardiac marker testing market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%.

Key Points: 
  • The global cardiac marker testing market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%.
  • Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market.
  • The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
  • Asia-Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period.

Cardiac Marker Testing Market worth $5.5 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, January 19, 2021

The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US).

Key Points: 
  • The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US).
  • Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market.
  • Asia Pacific likely to emerge as the largest cardiac marker testing market, globally
    Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period.
  • Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US) are the key players in the global cardiac marker testing market.

Cardiac Marker Testing Market worth $5.5 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, January 19, 2021

The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US).

Key Points: 
  • The cardiac marker testing market includes major Tier I and II suppliers like Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US).
  • Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market.
  • Asia Pacific likely to emerge as the largest cardiac marker testing market, globally
    Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period.
  • Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US) are the key players in the global cardiac marker testing market.

Cardiac Marker Analyzer Market Analysis 2011-2019 & 2020-2026 with the Impact of COVID-19

Retrieved on: 
Tuesday, July 21, 2020

DUBLIN, July 21, 2020 /PRNewswire/ -- The "Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 21, 2020 /PRNewswire/ -- The "Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals" report has been added to ResearchAndMarkets.com's offering.
  • The global Cardiac Marker Analyzer market is predicted to reach US$ 4.5 Billion by 2026.
  • Cobas H232 POC system permits rapid and easy determination of cardiac blood markers such as Troponin T, NT-proBNP, D-dimer, CK-MB and myoglobin.
  • Cardiac Marker Analyzer - Mergers, Acquisitions, Distribution, Partnership and Licensing Agreements
    The Cardiac Marker Analyzer Covered in the report are as follows:

The Global Cardiac Marker Testing Market is expected to grow from USD 2,976.65 Million in 2019 to USD 4,661.87 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.76%

Retrieved on: 
Wednesday, June 24, 2020

On the basis of Disease, the Cardiac Marker Testing Market is studied across Congestive Heart Failure and Myocardial Infarction.

Key Points: 
  • On the basis of Disease, the Cardiac Marker Testing Market is studied across Congestive Heart Failure and Myocardial Infarction.
  • On the basis of Type of Testing, the Cardiac Marker Testing Market is studied across Laboratory Testing and Point-Of-Care Testing.
  • On the basis of Geography, the Cardiac Marker Testing Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the modes and strategic moves considered suitable for entering the Global Cardiac Marker Testing Market?

Point of Care at the Forefront of COVID-19 Testing in Quest to Break Transmission Chain

Retrieved on: 
Friday, March 20, 2020

But for true intervention in doctors offices -- or even airports, many see so-called "point-of-care" (POC) IVD tests as the ideal solution.

Key Points: 
  • But for true intervention in doctors offices -- or even airports, many see so-called "point-of-care" (POC) IVD tests as the ideal solution.
  • A new report on worldwide point-of-care markets from IVD market researcher Kalorama Information has been released amid the coronavirus outbreak.
  • The report has markets for all kinds of near-patient testing -- everything from self-testing for glucose to rapid HIV tests to cardiac marker tests.
  • "To break a transmission chain, fast access is needed.

Cardiac Biomarkers - An Essential Tool in the Diagnosis and Management of Cardiovascular Diseases: Infinium Global Research

Retrieved on: 
Wednesday, March 4, 2020

Over the last 50 years, cardiac biomarkers are being used for primary and secondary prevention, the diagnosis and management of acute myocardial infarction (AMI), and the diagnosis and risk stratification of heart failure (HF).

Key Points: 
  • Over the last 50 years, cardiac biomarkers are being used for primary and secondary prevention, the diagnosis and management of acute myocardial infarction (AMI), and the diagnosis and risk stratification of heart failure (HF).
  • Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/13335
    The use of a large number of cardiac biomarkers is becoming a routine in clinical diagnosis, differential diagnosis, risk stratification, and prognosis and guides the management of patients with suspected cardiovascular diseases.
  • In particular, cardiac troponins have become the cardiac markers of choice for patients with ACS and is generating the maximum revenue in the cardiac biomarkers market.
  • Geographically, North America is expected to dominate the market in terms of revenue in the global cardiac biomarkers market.

The Global Cardiac Biomarkers Testing Market size is expected to reach $16.2 billion by 2025, rising at a market growth of 11.4% CAGR during the forecast period

Retrieved on: 
Wednesday, July 24, 2019

The Global Cardiac Biomarkers Testing Market size is expected to reach $16.2 billion by 2025, rising at a market growth of 11.4% CAGR during the forecast period.

Key Points: 
  • The Global Cardiac Biomarkers Testing Market size is expected to reach $16.2 billion by 2025, rising at a market growth of 11.4% CAGR during the forecast period.
  • Cardiac biomarkers or cardiac markers are endogenous substances which are released in the blood stream when the heart is damaged or stressed.
  • The recent product launches and further developments in the products are major growth trends which are providing lucrative growth opportunities to the cardiac biomarker market.
  • Moreover, the rising awareness in the developing countries regarding the use of PoC testing and its application in cardiac biomarkers has nurtured the market growth.

Global Cardiac Biomarkers Markets, 2018-2019 & 2019-2024: Focus on Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP & Ischemia Modified Albumin

Retrieved on: 
Tuesday, March 26, 2019

Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged.

Key Points: 
  • Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged.
  • Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS).
  • What is the structure of the global cardiac biomarkers market and who are the key players?
  • What is the degree of competition in the global cardiac biomarkers market?